Skip Navigation

Lymphoma Research Studies

Alemtuzumab (Campath) for T-LGL Lymphoproliferative Disorders - Protocol Description

Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders. The study drug, a monoclonal antibody, may help increase blood counts and reduce the number of abnormal T cell large granular lymphocytes. If eligible to participate, consenting subjects will receive an intravenous infusion of study medication alemtuzumab (Campath) once a day for 10 days. Subjects will be admitted to the NIH Clinical Center hospital for study drug initiation. If the study drug infusion is tolerated well, the subject may be discharged and receive the remainder of the treatment course as an outpatient.

If you have been diagnosed with T-LGL and are 18 years or older, you may be able to participate in this clinical trial. To find out if you qualify, please call our study coordinator at 301-496-4462 or email us at


HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome - Protocol Description

This research is with the Stem Cell Transplant Program investigating the use of allogeneic (donor) stem cell transplantation in patients with mycosis fungoides/Sezary syndrome who have no reasonable expectation of cure from available therapy. The transplant procedure usually involves the use of chemotherapy and replacement of bone marrow cells from a donor family member. Most of the procedures, including the transplant, are performed in the outpatient setting. Participants will have regularly scheduled follow-up monitoring visits for up to 5 years. Provisions for lodging and local travel will be provided consistent with NIH guidelines. There is no charge for medications, laboratory tests, examinations, procedures and/or clinic visits performed as part of this study.If you have any questions about this study, contact the research Coordinator, Tel. No. 301.594.8013 or


Ofatumumab for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma - Protocol Description

The purpose of this study is to evaluate the efficacy of ofatumumab in combination with chemotherapy for previously untreated patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma(SLL). Ofatumumab is FDA approved for treating CLL/SLL that is not responsive to other drugs. 

Participants will receive treatment at the NIH Clinical Center Day hospital and will be regularly scheduled for clinic visits at the NIH to evaluate the response to treatment. There is no charge for study-related medications, laboratory tests or examinations. Financial support towards the cost of lodging and travel is available based on NIH guidelines.
For questions about this study, please contact the research coordinator, Tel. No. 301- 402-0797 or



Stem Cell Transplant for High Risk Patients with Lymphoma  - Protocol Description

If you have been diagnosed with Non-Hodgkin's lymphoma or Hodgkin's Disease you may be able to participate in a stem cell transplant clinical trial designed to evaluate methods to decrease graft-versus-host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant procedure. 

You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor, which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft- versus-host disease. 

We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home. 

To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail:

Last Updated: July 31, 2015